LeMaitre Vascular
Burlington
About LeMaitre Vascular
LeMaitre Vascular, Inc. engages in the development, manufacture, and marketing of medical devices and implants for the treatment of peripheral vascular disease worldwide. Its products include embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters; perfusion catheters that temporarily perfuse blood and other liquids into the vasculature; carotid shunts to temporarily divert blood to the brain during the removal of plaque from the carotid artery; and laparoscopic cholecystectomy devices to inject dye into the cystic duct during laparoscopic cholecystectomy. The company also offers manual contrast injectors for the injection of contrast media into blood vessels; modeling catheters to apply radial pressure to the inside of an aortic stent graft for sealing; radiopaque tape to improve the precision of vascular and endovascular procedures; and remote endarterectomy devices to remove severe atherosclerotic blockages from the arteries of the leg. In addition, it provides valvulotomes for use as a bypass vessel to carry blood past diseased arteries to the lower leg or the foot; vascular grafts to bypass or replace diseased arteries; vascular patches that are synthetic and biological patches for use in closing incisions in a blood vessel; vein strippers for single-incision removal of varicose veins; and vessel closure systems to attach blood vessels for dialysis access. LeMaitre Vascular, Inc. markets its products through direct and indirect sales force, and distributors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $204.5M
- Funding stage: M&A
- Last round: Post-IPO Debt (Dec 2024)
- Ticker: nasdaq:LMAT
- Website: lemaitre.com
- Phone: 7814255049
Industries & Categories
Hardware, Health Care, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/lemaitre-vascular-7112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.